Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome

Fabian Fernandez, Wade Morishita, Elizabeth Zuniga, James Nguyen, Martina Blank, Robert C. Malenka, Craig C. Garner

Research output: Contribution to journalArticlepeer-review

384 Scopus citations

Abstract

Ts65Dn mice, a model for Down syndrome, have excessive inhibition in the dentate gyrus, a condition that could compromise synaptic plasticity and mnemonic processing. We show that chronic systemic treatment of these mice with GABAA antagonists at non-epileptic doses causes a persistent post-drug recovery of cognition and long-term potentiation. These results suggest that over-inhibition contributes to intellectual disabilities associated with Down syndrome and that GABAA antagonists may be useful therapeutic agents for this disorder.

Original languageEnglish (US)
Pages (from-to)411-413
Number of pages3
JournalNature neuroscience
Volume10
Issue number4
DOIs
StatePublished - Apr 2007
Externally publishedYes

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint

Dive into the research topics of 'Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome'. Together they form a unique fingerprint.

Cite this